TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23358514

Group type: EXPERIMENTAL
Intervention: CTD0.02 (0.02 mg CTD/kg body weight)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CTD1 (1 mg CTD/kg body weight)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CTD50 (50 mg CTD/kg body weight)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (0 mg CTD/kg body weight)
Number of subjects: 24
Study: 21289225

Group type: EXPERIMENTAL
Intervention: 85% energy density condition (with puréed vegetables)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 75% energy density condition (with puréed vegetables)
Number of subjects: 41

Group type: COMPARATOR
Intervention: 100% energy density condition (standard version)
Number of subjects: 41
Study: 19259838

Group type: EXPERIMENTAL
Intervention: Internet-based cultural competence course
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 122
Study: 16923699

Group type: EXPERIMENTAL
Intervention: Nebulized pentoxifylline (PTXF) 20 mg/kg (spontaneous breathing) or 10 mg/kg (ventilatory support) every 6 hours for 3 days
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (DX) 0.25 mg/kg every 12 hours for 3 days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (nebulized distilled water)
Number of subjects: 150
Study: 15059684

Group type: EXPERIMENTAL
Intervention: 4 units of alcohol (4 UA: 32 g ethyl alcohol, 1203.8 kJ)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1 unit of alcohol (1 UA: 8 g ethyl alcohol, 498.2 kJ)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No-alcohol lager (no-alcohol condition)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 units of alcohol (4 UA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1 unit of alcohol (1 UA)
Number of subjects: 12
Study: 11157561

Group type: EXPERIMENTAL
Intervention: Polymyositis and dermatomyositis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inclusion body myositis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls (muscular dystrophies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inflamed muscle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMP-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMP-9
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sera of affected patients
Number of subjects: 0
Study: 10806670

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 8167351

Group type: EXPERIMENTAL
Intervention: Busulfan (16 mg/kg, n = 88)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Total Body Irradiation (TBI, n = 79)
Number of subjects: 167
Study: 3048792

Group type: EXPERIMENTAL
Intervention: SMS 201‐995 (Sandostatin)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Angiotensin‐II (2‐10 ng/kg/min)
Number of subjects: 16
Study: 30008188

Group type: EXPERIMENTAL
Intervention: tamsulosin + solifenacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: tamsulosin
Number of subjects: 0
Study: 25642968

Group type: EXPERIMENTAL
Intervention: Early two-stage palatoplasty by the modified Furlow Technique (ETS)
Number of subjects: 71

Group type: COMPARATOR
Intervention: One-stage Wardill-Kilner push-back palatoplasty (PB)
Number of subjects: 71
Study: 25790835

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections at postoperative days 7 and 14
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no PRP injections)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PRP treatment
Number of subjects: 60
Study: 23897968

Group type: EXPERIMENTAL
Intervention: PCE (paclitaxel/carboplatin + enzastaurin)
Number of subjects: 142

Group type: COMPARATOR
Intervention: PC (paclitaxel/carboplatin + placebo)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: PCE
Number of subjects: 142

Group type: COMPARATOR
Intervention: PC
Number of subjects: 142
Study: 20420283

Group type: EXPERIMENTAL
Intervention: Dinoprostone vaginal insert (10 mg for 12 hours)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous oxytocin (20 IU during cesarean delivery)
Number of subjects: 200
Study: 18240245

Group type: EXPERIMENTAL
Intervention: PYD plus exercise
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: PYD plus diet recall but no exercise
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo plus exercise
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo plus diet recall but no exercise
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Exercise groups (PYD plus exercise and placebo plus exercise)
Number of subjects: 165
Study: 16803851

Group type: EXPERIMENTAL
Intervention: Bromocriptine (D2R agonist)
Number of subjects: 18
Study: 14529100

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg
Number of subjects: 554

Group type: COMPARATOR
Intervention: Albuterol 180 microg
Number of subjects: 554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study: 10637064

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin (50 mg/m²) plus intravenous epidoxorubicin (60 mg/m²) and intravenous cyclophosphamide (600 mg/m²)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Intravenous cisplatin (50 mg/m²) plus intravenous epidoxorubicin (60 mg/m²) and intravenous cyclophosphamide (600 mg/m²)
Number of subjects: 113
Study: 8892457

Group type: EXPERIMENTAL
Intervention: CY/TBI (120 mg/kg cyclophosphamide and 1320 cGy total body irradiation)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: BU/CY (16 mg/kg Busulfan and 200 mg/kg cyclophosphamide)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CY/TBI
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: BU/CY
Number of subjects: 75
Study: 1647496

Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg subcutaneous injection)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 6607245

Group type: EXPERIMENTAL
Intervention: Adjuvant CMF (6 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose CMFVP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three drug combination CAF (doxorubicin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAMELEON (sequentially alternating therapy) added to CAF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive combination chemotherapeutic approaches
Number of subjects: 0
Study: 30411521

Group type: EXPERIMENTAL
Intervention: 3D interactive software for acetabular fracture classification
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional 2D tutorial for acetabular fracture classification
Number of subjects: 30
Study: 29766633

Group type: EXPERIMENTAL
Intervention: Empagliflozin 2.5 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 26694940

Group type: EXPERIMENTAL
Intervention: Dorsalis pedis artery (DPA)
Number of subjects: 37
Study: 24065729

Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Online-based training
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (simulation and online)
Number of subjects: 12
Study: 22197080

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional Vocational Rehabilitation (CVR)
Number of subjects: 58
Study: 19779730

Group type: EXPERIMENTAL
Intervention: Cryotherapy at sclerotomy sites (two spots at each site)
Number of subjects: 88

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Cryotherapy at sclerotomy sites
Number of subjects: 88
Study: 17490659

Group type: EXPERIMENTAL
Intervention: Phytoestrogens (red clover and soy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phytoestrogens
Number of subjects: 0
Study: 15535111

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sibutramine
Number of subjects: 45
Study: 11275859

Group type: COMPARATOR
Intervention: Standard care (ice, elevation, and immobilization)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Standard care and ibuprofen
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Standard care and music distraction
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Higher pain ratings
Number of subjects: 77
Study: 9675382

Group type: EXPERIMENTAL
Intervention: esmolol 1 mg.kg‐1 + 200 micrograms.kg‐1.min‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: saline (control group)
Number of subjects: 40
Study: 7989509

Group type: EXPERIMENTAL
Intervention: Teratozoospermic group (T)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 68
Study: 2660557

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g three times a day
Number of subjects: 500

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice a day
Number of subjects: 500
Study: 7816004

Group type: EXPERIMENTAL
Intervention: Orange juice with K+ (35 mmol), Mg2+ (17 mmol), and HPO4(2‐) (39 mmol)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Orange juice only (without K- and Mg-phosphate supplementation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Orange juice with K- and Mg-phosphate supplementation
Number of subjects: 30
Study: 391578

Group type: EXPERIMENTAL
Intervention: tienilic acid
Number of subjects: 56

Group type: COMPARATOR
Intervention: hydrochlorothiazide
Number of subjects: 56
Study: 30093119

Group type: EXPERIMENTAL
Intervention: Immediate loading
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional loading
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study: 28240625

Group type: EXPERIMENTAL
Intervention: In SHAPE program (gym membership, weekly individual meetings with a fitness trainer, instruction on healthy eating and nutrition)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: In SHAPE program
Number of subjects: 343

Group type: COMPARATOR
Intervention: Gym membership control condition
Number of subjects: 343
Study: 25648347

Group type: EXPERIMENTAL
Intervention: FMI tablet (500 mg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: HF meal (with FMI tablet 300 mg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: LF meal (with FMI tablet 300 mg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: NM (with FMI tablet 300 mg)
Number of subjects: 63
Study: 24463669

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg once daily during catheterization
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 20922510

Group type: EXPERIMENTAL
Intervention: Balance Project intervention (five-session, individually delivered coping skills intervention)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 249
Study: 19620077

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy at 3.0 Gy/fraction (30 Gy total) combined with weekly docetaxel at 60 mg for 2 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Radiotherapy alone at 2.0 Gy/fraction (40 Gy total)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 72
Study: 17517703

Group type: EXPERIMENTAL
Intervention: BF‐1 fermented milk
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 15363024

Group type: EXPERIMENTAL
Intervention: Cultural and Self‐Empowerment Group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Modified Cultural Group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Traditional Group
Number of subjects: 15
Study: 11474385

Group type: EXPERIMENTAL
Intervention: Routine sedation with midazolam (0.07 mg/kg) and meperidine (0.77 mg/kg)
Number of subjects: 249

Group type: COMPARATOR
Intervention: On demand sedation with midazolam and meperidine
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Routine sedation with midazolam and meperidine
Number of subjects: 249
Study: 9924308

Group type: EXPERIMENTAL
Intervention: Silicone IOLs
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PMMA IOLs
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Polyacrylic IOLs
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (PMMA and silicone IOLs)
Number of subjects: 90
Study: 8055491

Group type: EXPERIMENTAL
Intervention: Relaxation and visualization training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Relaxation, visualization, and cognitive coping skills training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 3291895

Group type: EXPERIMENTAL
Intervention: nifedipine 30 mg po
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study: 31538488

Group type: EXPERIMENTAL
Intervention: Peer support intervention (6-weekly visits from a peer support worker in addition to routine care)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (routine care alone including contact with a midwife and access to a GP if required)
Number of subjects: 20
Study: 31679018

Group type: EXPERIMENTAL
Intervention: High-heat capacity mattress
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional low-heat capacity mattress
Number of subjects: 0
Study: 26482148

Group type: EXPERIMENTAL
Intervention: Cherry juice (200 ml/day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control juice (negligible anthocyanin content)
Number of subjects: 49
Study: 26289448

Group type: EXPERIMENTAL
Intervention: High-frequency telephone-delivered lifestyle support (10 times)
Number of subjects: 2607

Group type: EXPERIMENTAL
Intervention: Low-frequency telephone-delivered lifestyle support (3 times)
Number of subjects: 2607

Group type: EXPERIMENTAL
Intervention: Middle-frequency telephone-delivered lifestyle support (6 times)
Number of subjects: 2607

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 2607
Study: 24013186

Group type: EXPERIMENTAL
Intervention: Etamicastat
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Human recombinant NAT1 and NAT2 enzymes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Human single-donor enzymes
Number of subjects: 8

Group type: COMPARATOR
Intervention: p-aminosalicylic acid
Number of subjects: 8
Study: 22290680

Group type: EXPERIMENTAL
Intervention: iv lornoxicam (8 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: iv paracetamol (1 g)
Number of subjects: 60

Group type: COMPARATOR
Intervention: iv saline solution (Control)
Number of subjects: 60
Study: 19597368

Group type: EXPERIMENTAL
Intervention: P-OM3 + FENO (4 g QD + 130 mg QD)
Number of subjects: 163

Group type: COMPARATOR
Intervention: FENO (130 mg QD)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: P-OM3 added to FENO monotherapy during open-label extension
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: P-OM3 + FENO in second open-label extension
Number of subjects: 163
Study: 16716211

Group type: EXPERIMENTAL
Intervention: Walking group (two 45 minute walks per week)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 37
Study: 15575109

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise program with a refrigerator magnet education tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper copy education tool
Number of subjects: 0
Study: 10980880

Group type: EXPERIMENTAL
Intervention: Systemic anticoagulation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 9001369

Group type: EXPERIMENTAL
Intervention: Supplementation
Number of subjects: 122

Group type: COMPARATOR
Intervention: Non-supplemented children
Number of subjects: 122
Study: 1455811

Group type: EXPERIMENTAL
Intervention: Combined action of bitemporal UHF electric field and decimeter waves
Number of subjects: 0
Study: 3967455

Group type: COMPARATOR
Intervention: Placebo (0 mg amantadine)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 25 mg amantadine
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 100 mg amantadine
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 150 mg amantadine
Number of subjects: 74
Study: 29588170

Group type: EXPERIMENTAL
Intervention: Lira‐basal (0.9 mg/day liraglutide plus basal insulin)
Number of subjects: 50

Group type: COMPARATOR
Intervention: BBIT (basal-bolus insulin therapy)
Number of subjects: 50
Study: 28472303

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) training (3 × 3 minutes twice daily for 5 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Regular care (Control)
Number of subjects: 24
Study: 25445405

Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook. f. (TwHF) 1.5 mg/kg/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Azathioprine 2.0 mg/kg/day
Number of subjects: 90
Study: 23439102

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1800

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: CABG (low SYNTAX scores)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: PCI (low SYNTAX scores)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: CABG (left main coronary disease)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: PCI (left main coronary disease)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: CABG (intermediate SYNTAX scores)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: PCI (intermediate SYNTAX scores)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: CABG (high SYNTAX scores)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: PCI (high SYNTAX scores)
Number of subjects: 1800
Study: 21386986

Group type: EXPERIMENTAL
Intervention: Ne-IC (Independent Component) in older subjects
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ne-IC contribution in older subjects
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Reaction Time (RT) distribution parameters
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: General behavior of older participants
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ne decline in elderly
Number of subjects: 2
Study: 18376221

Group type: EXPERIMENTAL
Intervention: Pd-103 brachytherapy
Number of subjects: 602

Group type: COMPARATOR
Intervention: I-125 brachytherapy
Number of subjects: 602
Study: 17557467

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Information-Only Control (IC)
Number of subjects: 35
Study: 14696664

Group type: EXPERIMENTAL
Intervention: Implant-retained overdenture (IRO)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Conventional complete denture (CD)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Endosseous implants
Number of subjects: 121
Study: 10361178

Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection (UD) group (n = 27)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional (CV) group (n = 31)
Number of subjects: 58
Study: 8697067

Group type: EXPERIMENTAL
Intervention: Orlistat 50 mg three times a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orlistat 10 mg, 60 mg, and 120 mg three times a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0
Study: 1781526

Group type: EXPERIMENTAL
Intervention: Adrenaline 1:200,000 administered 5 minutes before 20 ml bupivacaine 0.5%
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline followed by 20 ml bupivacaine 0.5% with 100 micrograms adrenaline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline followed by 20 ml plain bupivacaine 0.5%
Number of subjects: 24
Study: 7014790

Group type: EXPERIMENTAL
Intervention: Steroid group (5 mg/kg/day of methylprednisolone)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonsteroid group (no drug)
Number of subjects: 100
Study: 31094229

Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pre-cooling
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Supplementation with pre-cooling
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 30304936

Group type: EXPERIMENTAL
Intervention: Telephone contact within 2-4 days of release by a continuity clinic coordinator, who scheduled and informed the ex-detainees of their appointment date within 6 weeks post-release plus standard of care.
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard of care (comprehensive discharge planning, offering substance abuse treatment, provision of information on self-scheduling appointments).
Number of subjects: 110
Study: 27091235

Group type: EXPERIMENTAL
Intervention: Waiting group (5 min after peri-prostatic nerve block)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no waiting after peri-prostatic nerve block)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study: 25503600

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS) 5, 10, and 20 μg/h (maximum dosage of 20 μg/h)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Sustained-release tramadol tablets 100 mg (maximum dosage of 400 mg/d)
Number of subjects: 280
Study: 23792641

Group type: EXPERIMENTAL
Intervention: PF-3512676 (0.20 mg/kg injected subcutaneously once weekly) plus erlotinib (150 mg daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: erlotinib alone (150 mg daily)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PF-3512676 plus erlotinib
Number of subjects: 39

Group type: COMPARATOR
Intervention: erlotinib alone
Number of subjects: 39
Study: 22929598

Group type: EXPERIMENTAL
Intervention: Data-driven quality improvement in primary care (DQIP) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 19762706

Group type: EXPERIMENTAL
Intervention: Prophylactic, catheter‐based normothermia (CoolGard; body core temperature 36.5 degrees C)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional, stepwise fever management with anti‐inflammatory drugs and surface cooling
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Prophylactic normothermia
Number of subjects: 102
Study: 18161263

Group type: EXPERIMENTAL
Intervention: Rimonabant
Number of subjects: 0